Related Experiment Videos
Beta1-blocker (practolol) and exercise in patients with chronic obstructive lung disease
Acta Medica Scandinavica
|January 1, 1976
Summary
Practolol, a beta1-blocker, had minimal impact on lung function (FEV1) in patients with chronic obstructive lung disease during exercise. Circulatory effects were observed, but no significant adverse respiratory events occurred.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- Chronic obstructive lung disease (COPD) affects respiratory and circulatory functions.
- Beta-blockers are used for cardiovascular conditions but may impact respiratory function.
Purpose of the Study:
- To investigate the effects of practolol on ventilatory and circulatory parameters in COPD patients during exercise.
- To assess the clinical significance of practolol's impact on lung function in COPD.
Main Methods:
- Double-blind, cross-over study involving 20 COPD patients.
- Exercise testing on a bicycle ergometer with intravenous practolol or placebo.
- Measurement of ventilatory (FEV1, PaCO2, PaO2) and circulatory (Q, HR, BP) data.
Main Results:
- Practolol showed minimal reduction in FEV1 (8%) post-exercise compared to placebo.
- Observed expected beta1-blocking effects: maintained cardiac output (Q), reduced heart rate (HR), and lowered blood pressure (BP).
- No significant difference in PaO2; slight decrease in PaCO2 post-exercise with practolol.
Conclusions:
- Practolol, even at doses with maximal circulatory effects, has a slight but clinically insignificant impact on ventilatory parameters in COPD patients.
- The observed reduction in FEV1 was positively correlated with the fall in heart rate.
- No adverse respiratory symptoms like wheezing or dyspnea were attributed to practolol.